Search Results

Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, announced that it has entered into a clinical collaboration with Merck, to evaluate DF9001, Dragonfly’s EGFR immune engager, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA®, in patients with advanced solid tumors expressing EGFR.

Dragonfly Therapeutics, Inc. announced a new clinical collaboration designed to evaluate and combine DF1001, a HER-2 immune engager developed using Dragonfly’s TriNKET technology platform and Dragonfly’s lead clinical asset, with Trodelvy, Gilead’s Trop-2-directed antibody drug conjugate, in metastatic breast cancer and non-small cell lung cancer.

Dragonfly Therapeutics, Inc. announced receipt of a milestone payment following dosing of the first patient in a clinical trial conducted by AbbVie to evaluate ABBV-303, a solid tumor targeting TriNKET®.

Dragonfly Therapeutics, Inc. today announced it recently dosed its first patient in a Phase 1/1b study of the Company’s proprietary IL-2 investigational immunotherapy, DF6215, developed for patients with advanced solid tumors.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Dragonfly Therapeutics, Inc. today announced that Bristol Myers Squibb exercised its option to enter into an exclusive license for a sixth TriNKET Immunotherapy drug candidate, that will bring the total drug candidates licensed by Bristol Myers Squibb to seven including Dragonfly’s novel IL12 cytokine DF6002/BMS-986415.